AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that its management team is scheduled to parti…
AngioDynamics Inc reported fiscal 2026 revenue of $320.17M, up 9.5% from $292.5M a year earlier, while the company recorded a net loss of ($36.74M) and diluted loss per share of ($0.88) for the year — a slightly larger loss versus fiscal 2025. This summary is based on the company's Form 10-K for th…
Revenue grew 9.5% to $320.2M, led by Med Tech segment growth and improved gross margin, but net loss widened to $36.7M due to higher operating expenses and restructuring. Strategic divestitures and cost-saving initiatives are underway, with strong liquidity and a focus on high-growth platforms.Orig…
Revenue grew 9.4% to $320.2M in fiscal 2026, led by 18% Med Tech growth and margin expansion despite tariffs. Guidance for 2027 calls for 5–6.5% revenue growth, 12–15% Med Tech growth, and continued investment in R&D and clinical data.Based on AngioDynamics, Inc. [ANGO] Q4 2026 Audio Transcript — J…
Delivered strong FY2026 results with 9.4% revenue growth and expanding MedTech segment, driven by robust performance in Auryon, AlphaVac, and NanoKnife. FY2027 guidance projects continued MedTech growth, stable margins, and ongoing investment in clinical data and innovation.Based on AngioDynamics…
Accelerated growth in FY 2026 was led by the Med Tech segment, with strong revenue and margin expansion. FY 2027 guidance anticipates continued double-digit Med Tech growth, stable Med Device sales, and robust cash flow, supported by a strong balance sheet.Original document: AngioDynamics, Inc. [AN…
ANGO (AngioDynamics, Inc.) is set to announce its Q4'25 results on July 14, after the market closes. The earnings are expected to be disclosed at 9:30 AM ET (1:30 PM UTC).For Q4'25, revenue estimate is 80.24 million USD with EPS (earnings per share) anticipated at (0.09) USD. Learn more details at…
